Life sciences leaders from Greater Philadelphia represented the region at BIO Digital 2021, participating in discussions on topics including “diversity and equity in scientific innovation” and “realizing the promise of gene therapy.”
The contract development and manufacturing organization (CDMO) announced it will open a new pharmaceutical manufacturing campus in Middletown, Delaware in 2024, bringing 500 new jobs to the region by 2026.
A shared goal of attracting talent to Greater Philadelphia’s cell and gene therapy hub has united 18 companies who form the Life Science Talent Pipeline Collaborative.
Eleven highly connected counties comprise Greater Philadelphia, and spread throughout the entire region are employers dedicated to the discovery, commercialization, and delivery of cell and gene therapies. The result is accessibility to rewarding employment opportunities regardless of preference for urban, suburban, or rural living.
Among the life sciences deals for the first quarter of 2021 were nine transactions in the cell and gene therapy space totaling more than $980 million.
CEO Council for Growth's Executive Director Claire Greenwood submitted this letter to the editor in The Philadelphia Inquirer to emphasize the importance of investing in this sector to support the growth of our region.
For the nearly 5,000 employees working cell & gene therapy who call Philadelphia home, it has proven to be the best of both worlds with attributes that satisfy both your personal and professional life.
Claire Greenwood, Executive Director, CEO Council for Growth, and Patricia Day, Manager, Leadership Engagement, the Chamber of Commerce for Greater Philadelphia elaborate on the creation of the Life Science Talent Pipeline Collaborative in an op-ed originally published at CellandGene.com.
The critically important work of the life sciences industry globally has been front and center as health care providers, researchers, manufacturers and distributors collaborate to respond to the coronavirus pandemic.
The Greater Philadelphia region’s reputation as a center for the cell and gene therapy industry grew in 2020 as breakthrough research from industry academia pioneers is increasingly complemented by strong capital investment and real estate projects meeting the specialized land, building, and lab development needs of start-up, scaling and relocating companies.
Investment
According to research from biopharma database company DealForma (as of December 9, 2020), the Greater Philadelphia region saw 49 life sciences investment deals in 2020, valued at more than $12 billion, including six in the cell and gene therapy space totaling $4.5 billion. Among the cell and gene therapy investment […]
